Literature DB >> 26424831

Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.

Athena P Kourtis1, Jeffrey Wiener2, Tiffany S Chang3, Sheila C Dollard2, Minal M Amin2, Sascha Ellington2, Dumbani Kayira4, Charles van der Horst5, Denise J Jamieson2.   

Abstract

Cytomegalovirus (CMV) infection is common among infants of HIV-infected mothers in resource-limited settings. We examined the prevalence and timing of infant CMV infection during the first year of life using IgG antibody and avidity among HIV-exposed infants in Malawi and correlated the results with the presence of detectable CMV DNA in the blood. The Breastfeeding, Antiretrovirals and Nutrition (BAN) study randomized 2,369 mothers and their infants to maternal antiretrovirals, infant nevirapine, or neither for 28 weeks of breastfeeding, followed by weaning. Stored plasma specimens were tested for CMV IgG and antibody avidity from a random subset of infants who had been previously tested with blood CMV PCR and had available specimens at birth and at 24 and 48 weeks of age. Ninety-four of 127 infants (74.0%) tested at 24 weeks of age had CMV IgG of low or intermediate avidity, signifying primary CMV infections. An additional 22 infants (17.3%) had IgG of high avidity; 19 of them had CMV DNA detected in their blood, indicating infant infections. Taken together, these results show that the estimated prevalence of CMV infection at 24 weeks was 88.9%. By 48 weeks of age, 81.3% of infants had anti-CMV IgG; most of them (70.9%) had IgG of high avidity. The CMV serology and avidity testing, combined with the PCR results, confirmed a high rate of primary CMV infection by 6 months of life among breastfeeding infants of HIV-infected mothers. The CMV PCR in blood detected most, but not all, infant CMV infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26424831      PMCID: PMC4658584          DOI: 10.1128/CVI.00460-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  31 in total

1.  Severe infections in HIV-exposed uninfected infants: clinical evidence of immunodeficiency.

Authors:  A L Slogrove; M F Cotton; M M Esser
Journal:  J Trop Pediatr       Date:  2009-07-14       Impact factor: 1.165

2.  Severe morbidity and mortality with breast milk associated cytomegalovirus infection.

Authors:  Mitchell Hamele; Ryan Flanagan; C Adam Loomis; Tracy Stevens; Mary P Fairchok
Journal:  Pediatr Infect Dis J       Date:  2010-01       Impact factor: 2.129

3.  Overview of human cytomegalovirus pathogenesis.

Authors:  Maciej T Nogalski; Donna Collins-McMillen; Andrew D Yurochko
Journal:  Methods Mol Biol       Date:  2014

Review 4.  The HIV-exposed, uninfected African child.

Authors:  Suzanne Filteau
Journal:  Trop Med Int Health       Date:  2009-01-20       Impact factor: 2.622

Review 5.  Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.

Authors:  Aileen Kenneson; Michael J Cannon
Journal:  Rev Med Virol       Date:  2007 Jul-Aug       Impact factor: 6.989

6.  High human cytomegalovirus loads and diverse linked variable genotypes in both HIV-1 infected and exposed, but uninfected, children in Africa.

Authors:  M Bates; M Monze; H Bima; M Kapambwe; F C Kasolo; U A Gompels
Journal:  Virology       Date:  2008-10-16       Impact factor: 3.616

7.  Acute cytomegalovirus infection in Kenyan HIV-infected infants.

Authors:  Jennifer A Slyker; Barbara L Lohman-Payne; Grace C John-Stewart; Elizabeth Maleche-Obimbo; Sandra Emery; Barbra Richardson; Tao Dong; Astrid Kn Iversen; Dorothy Mbori-Ngacha; Julie Overbaugh; Vincent C Emery; Sarah L Rowland-Jones
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

8.  Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies.

Authors:  Marion Ritter; Tina Schmidt; Jan Dirks; Pia Hennes; Ingolf Juhasz-Böss; Erich F Solomayer; Ludwig Gortner; Barbarac Gärtner; Tilman Rohrer; Urban Sester; Martina Sester
Journal:  Eur J Immunol       Date:  2013-01-31       Impact factor: 5.532

9.  High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa.

Authors:  Nyaxewo Mwaanza; Lophina Chilukutu; John Tembo; Mwila Kabwe; Kunda Musonda; Monica Kapasa; Chishala Chabala; Sylvester Sinyangwe; Peter Mwaba; Alimuddin Zumla; Matthew Bates
Journal:  Clin Infect Dis       Date:  2013-11-21       Impact factor: 9.079

Review 10.  New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection.

Authors:  Sheila C Dollard; Scott D Grosse; Danielle S Ross
Journal:  Rev Med Virol       Date:  2007 Sep-Oct       Impact factor: 6.989

View more
  3 in total

1.  CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding.

Authors:  Maria Franca Pirillo; Giuseppe Liotta; Mauro Andreotti; Haswel Jere; Jean-Baptiste Sagno; Paola Scarcella; Sandro Mancinelli; Ersilia Buonomo; Roberta Amici; Maria Cristina Marazzi; Stefano Vella; Leonardo Palombi; Marina Giuliano
Journal:  Med Microbiol Immunol       Date:  2016-09-15       Impact factor: 3.402

Review 2.  Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review.

Authors:  Sascha R Ellington; Kristie E N Clarke; Athena P Kourtis
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

3.  Human Immunodeficiency Virus Exposure but Not Early Cytomegalovirus Infection Is Associated With Increased Hospitalization and Decreased Memory T-Cell Responses to Tetanus Vaccine.

Authors:  Christiana Smith; Natasha O Moraka; Maryanne Ibrahim; Sikhulile Moyo; Gloria Mayondi; Betsy Kammerer; Jean Leidner; Simani Gaseitsiwe; Shaobing Li; Roger Shapiro; Shahin Lockman; Adriana Weinberg
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.